MedTrace Logo

Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score

NCT04677608 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-12-21

No results posted yet for this study

Summary

Pulmonary Arterial Hypertension (PAH) is a chronic disease characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to right ventricular (RV) failure, and ultimately death.

Different studies have outlined how various factors as vascular resistance, functional class, age, correlate with mortality. However, the modality of death and risk factors for mortality in patients with PAH are little known. For this purpose, more studies are necessary to analyze the risk factors related to modality of death in PAH.

Conditions

Sponsors & Collaborators

  • iPHNET (italian Pulmonary Hypertension NETwork)

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-21
Primary Completion
2021-04-30
Completion
2022-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04677608 on ClinicalTrials.gov